Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study [Corrigendum]


The Acknowledgement implies that Bayer Pharmaceuticals sponsored the study, this is not correct. The acknowledgement should state: The authors take full responsibility for the scope, direction, and content of the manuscript, and have approved the submitted manuscript. Medical writing support was provided by Corey Eagan, MPH, of PAREXEL, and was funded by Bayer Pharmaceuticals.